Azacitidine
Mixed Phenotype Acute Leukemia
Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 73/ 100
Competitive context
71 Active assets in the Mixed Phenotype Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin St. Jude Children's Research Hospital | Phase 4 | BB |
Cytosin-Arabinosid Children's Oncology Group | Phase 4 | BB |
ETOPOSIDE Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
DEXAMETHASONE St. Jude Children's Research Hospital | Phase 4 | BB |
METHOTREXATE Children's Oncology Group | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →